NOVEL VARIANT, ENTEROCOCCUS FAECALIS BR2 HAVING RIFAMPICIN AND ANTIBIOTICS-RESISTANCE

摘要

PURPOSE: Provided is novel variant Enterococcus faecalis BR2(deposit No. KFCC-11075 deposited in December 17, 1998), which has a resistance to rifampicin and various antibiotics and exhibits the whole intestinal regulation properties of a parent strain. Therefore, the mutant is used in the treatment of intestinal disease of the patients receiving antibiotics. CONSTITUTION: A Enterococcus faecalis BR2 is a mutant of Enterococcus faecalis BIO strain, which is produced by conferring the resistance of rifampicin and other antibiotics to the parent strain. A preparation comprising the lactic acid bacteria, a carrier, a flavor and other additives is excellent in resistance to the antibiotics and increases the survival ratio of the lactic acid bacteria within the intestinal.